Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vigilant Biosciences

Request full access

Vigilant Biosciences | Transforming Detection To Improve Outcomes

Lakeway, United StatesFounded 2011Biotech & Life Sciences

About Vigilant Biosciences

Vigilant Biosciences, established in 2011, is a medical technology firm centered on the development of solutions for the early detection of cancer. The company was founded by Matthew H.J. Kim, who was reportedly inspired by his parents' experiences with cancer. Since its inception, the company has progressed through several funding stages, securing approximately $29.8 million over five rounds, including a significant Series B round. Key investors include the Florida Institute, venVelo, and White Owl Capital Partners. A notable achievement for the company was receiving the FDA's Breakthrough Device Designation in March 2023 for its flagship product, a step that expedites the development and review process for novel medical devices.

The firm operates in the oncology and diagnostic equipment market, providing tools for healthcare professionals, particularly those in dentistry, to aid in the early identification of oral and oropharyngeal cancer. Its business model revolves around the sale of its diagnostic systems and associated tests to clinicians and healthcare providers. While the company's products are available in select international markets under CE Mark approval, they are not yet for sale in the United States, pending further regulatory clearance. The company has established a CLIA-certified laboratory, OncAlert Labs, to process tests in the U.S. market once approved.

Vigilant Biosciences' primary offering is the BeVigilant™ OraFusion System. This point-of-care system is designed to identify patients at risk for oral cancer through a non-invasive oral rinse. The technology works by measuring specific tumor-initiating and stem cell-associated biomarkers—specifically soluble CD44 and total protein levels—which are clinically associated with the presence of oral cancer, sometimes before visible symptoms appear. The system provides results in approximately 15 minutes during a patient's visit. It targets high-risk populations, including tobacco users, those with excessive alcohol consumption, and individuals with HPV-16. The OraFusion test uniquely combines biomarker detection with artificial intelligence software that considers clinical risk factors to assess a patient's risk.

Source: Dealroom company data

Vigilant Biosciences in the Lakeway ecosystem

Live from Dealroom

The Vigilant Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A1 investor entered at this stage

  • venVelo
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States92.9%
🇮🇳 India7.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vigilant Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vigilant Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.